EU drug regulator finds link between AstraZeneca vaccine and blood clots
Europe's drug regulator on Wednesday found a possible link between AstraZeneca's COVID-19 vaccine and rare blood clotting issues in adults who had received the shot and said it had taken into consideration all currently available evidence.
- World
- AP
- Published Date: 05:10 | 07 April 2021
- Modified Date: 06:48 | 07 April 2021
The EU's drug regulator says it has found a "possible link" between the AstraZeneca coronavirus vaccine and a rare clotting disorder but said that the benefits of the shot still outweigh risks.
In a statement released Wednesday, the European Medicines Agency placed no new restrictions on using the vaccine in people 18 and over.
The EMA said most of the cases reported have occurred in women under 60 within two weeks of vaccination. The agency said based on the currently available evidence, it was not able to identify specific risk factors. Experts reviewed several dozen cases that came mainly from Europe and the United Kingdom, where around 25 million people have received the AstraZeneca vaccine.
"The reported cases of unusual blood clotting following vaccination with the AstraZeneca vaccine should be listed as possible side effects of the vaccine," said Emer Cooke, the agency's executive director.
In March, more than a dozen countries, mostly in Europe, suspended their use of AstraZeneca over the blood clot issue. Most restarted — some with age restrictions — after the EMA said countries should continue using the potentially life-saving vaccine.
The suspensions were seen as particularly damaging for AstraZeneca because they came after repeated missteps in how the company reported data on the vaccine's effectiveness and concerns over how well its shot worked in older people. That has led to frequently changing advice in some countries on who can take the vaccine, raising worries that AstraZeneca's credibility could be permanently damaged, spurring more vaccine hesitancy and prolonging the pandemic.